TMO - Earnings call transcript Q1 2019 | Thermo Fisher Scientific Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2019 First Quarter Conference Call. My name is Krista, and I'll be your conference operator today. [Operator Instructions]. Thank you. I would like to introduce our moderator for the call, Mr. Investor President, Vice Apicerno, Relations. Ken Mr. begin Apicerno, call. you may the

Kenneth Apicerno

for morning, and us. you thank Good joining

XXXX with is be Senior me President call webcast note the On today is call the Executive Chief A of Officer. being heading website and Investors that thermofisher.com, and and of this and Results. Presentations and Marc Officer; section Stephen quarter XXXX. on under our XX, President release press Williamson, the Investors Webcasts will Vice and live Financial Please is archived copy Chief website, under our expectations the Casper, section our May of the Financial future available earnings first until the on heading our of

on caption Securities statement. result future that the the these purposes factors, Act So under make Actual as Private SEC about also plans Investors December including Various the website expectations, in of may by the provisions XX, the before forward-looking Litigation discussed our year on under those important from under on for annual begin, safe various heading and filings. Securities report remarks XXXX, Exchange the statements the me we we statements Commission company's let indicated forward-looking those company's prospects briefly and results materially Reform constitute Form cover harbor is ended may the for factors, which XX-K of differ XXXX. file safe available a with the risk and harbor section of our of

directly Therefore, should of during our as to this Also our we comparable future earnings forward-looking referring with these press Investors forward-looking the our do non-GAAP prepared on to not be available measures GAAP not also specifically most obligation the we'll today. in subsequent rely accordance quarter website statements and any any representing of may certain in these at you measures principles, update release our on change. to some generally future, and While if Financial the as Information. we so estimates call, financial even XXXX views date A in to elect expectations GAAP. disclaim accounting under to statements point the reconciliation is heading the measures of accepted of financial or section first

So I'll with turn over now call Marc. that, the to

Marc Casper

good our Thanks, QX for Thank Ken, joining today and morning, for call. us everyone. you

As the on another press you delivered growth release, strong had to excellent bottom quarter our in we top a both start the year. of and saw line. We

strategy We customer the growth put serve leadership strongest number We on and our our strengthened value and high-growth in new proposition. our of products, unique to continue our effectively Thermo Fisher capitalized to in position markets to customers. execute launched emerging a innovative

per capital stock EPS financials. Bio topics in depth returning also let We first, of a $X.XX capital, announcing to the share. increase remarks, deploy effectively buybacks We but to continue of Brammer performance, I'll our quarter more dividends. each in delivered me our cover and shareholders and through achieving recap acquisition our strong another XX% adjusted of to these my

in year-over-year revenue X% Our $X.XX grew QX billion. to

increased XX.X%. for QX in Our quarter operating adjusted the income adjusted X% our margin billion, operating increased $X.XX we to first and to

major markets our regions. we captured to share. had for been time seeing well needs gain growth in our of we've our conditions saw our across meet to good XXXX. and executed of and customers momentum perspective, carry team a our effectively into geographic So strong the and growth The QX, in strong the some growth all opportunities drive continued we From we end

end pharma growth market end delivered strong, by quarter. during and This you on provide color me market. double-digit biotech. the and with some with Let very performance remained our Starting we

that serve see We strength to our businesses broad-based customers. in continue these

proposition value academic for low As help you customer government, across growth and know, business. to biotech single-digit productivity innovation we pharma a because QX. enhance their we them in In and can and we had accelerate have unique

China, Looking conditions good North at another this muted in in and America end market more conditions from in strong lens, Europe. we a saw geographic delivered quarter

diagnostics Turning care. delivered health this with immunodiagnostics during and clinical from digits quarter our contributions and businesses. to We mid-single diagnostics strong

applied, Finally, in industrial in a QX. growth and we high delivered single-digit

Our across performance, great performance Instrument by by summarize strong strength a Analytical To our this year quarter. was -- was led it our businesses.

gain the conditions on in good we market capitalized end to teams and our markets, Our continued share.

see our of growth the our in impact strategy You clearly results. can

touch of business our in me some let on Now highlights the quarter.

leveraging execute our you customer continue continuing formula products, create our X off start innovative with expect This pillars: value competitive scale know, great is a our with from come as I'll kicked and clear range to launching our and we innovation customers. on launches. advantage markets we for to the product high-growth is and with of well proposition. you've to a year success, new us, based in new emerging and As strategy enhance to our

Thermo Thermo new new designed advanced FDA date. show we complex analysis a products we in regulations. beam system to a the time TSQ the take Nicolet a Scientific workflow me that productivity. develop customers new safety unveiled sample spectrometer, month at animal standard quad food In sets And to mass to Analytical advanced mass high-volume This nanoscale. Helios and spectroscopy, molecular system in provides required to materials. we sensitive triple Specialty protein certain blood a the customers to feedback help reactions. Summit enable levels peanut which designed new terms a incorporates and DualBeam, teaching a is scanning in we dioxins real-time our the event. at in may XXXX Nicolet that enable customer Shanghai, GC in better showcased materials allergies. quality a preventing moment trade most can a can This peanuts patients designed chromatography new dioxin spec to under QA/QC our by to Let using changer Diagnostics, life-threatening In of ion on received that introduced brand. we test doctors helping FTIR allergic detect a characterization European now feed, is X ImmunoCAP major be and perform and lower for optimize for reduces allergy industry in At last and Union Summit analyzer identify spectroscopy, appropriately of to by This and just electron is It Pittcon for for cause Scientific be game managing patients our materials characterization. our severe which highlight Instruments, laboratories The and microscope test latest their analysis number at clearance focused products for few. Last, highly launched

second the pillar to strategy. our Turning growth of

performance to our month, Asia for leveraging across Our continued XX% opportunities of our the to technologies better in our continue across pollution customer and reflects this air medicine, meet And our China in customers. continue the customers Pacific be create strong business demand I competitive to Asia to to our outstanding growth quarter markets another continues you flourishing growth experience enable how earlier on high-growth region significant In we than growth. there's give reduce lot our to well the industry-leading was strengthen and in our from of We're about scale of off strong, to Building build an examples. few a scale enthusiasm these XXXX, a and and advantage. delivering ahead. we're and see emerging biotech our providing industry China markets. precision we end advance specifically, broad-based colleagues

beverage facilities food to part to meet most well more These For to ceremony and deliver placed the our our Clearly, scientists more Solution lot demand. new Beijing to our emerging manufacturing we recent great to Customer expansion example industry to opportunity we and develop execute markets, consistently and how improve Delhi, agencies the is of that deliver strategically continue safety. took a efficiently workflows customers ribbon-cutting in are effectively. Centers globally and to continue and example, in in a strong help help quality high-growth in celebrate partners to and we I regulatory there. the new scientists, growing advanced analytical instrument Singapore, of opened operations collaborate In This performance. scale products and

proposition. growth customer third the of value pillar to Turning our strategy: our

across customers example is our is meet and as goals. great biotech, them you end We which capabilities to A company pharma know, help leverage market. their increase fastest-growing our continue to our and and the largest

and that us depth access these in differentiates scale, industry-leading have serving customers. We

to on commercial partner Importantly, development we stronger an them continue from build to drug research our to stage, even position be manufacturing. every at to for

to significant more biotech a pharma in was and vector cell agreement Brammer Bio customers diseases. the highlights our patients in One Bio is rare $X.X billion. to and gene manufacturing, helping therapies Brammer viral quarter for with the breakthrough leader provide of acquire

portfolios be genetic material effectively usually the battling genes so the exciting number inside unique Parkinson's. viral also better therapies into used gene hemophilia, disease. services As therapies to Bio who complements market gene using in capabilities the has a ALS patients This of serving in diseases be delivered these majority than Bio because you of is expertise or therapy capabilities close. types. great Brammer genes patient's altering carry and to treat a a These like promise different therapy viral leading the Modified and at pharma has bioproduction Brammer trials. why it cure novel of position supporting our clinical virus because business annually. vector involve know, and cover our expands will XX% they of are can a cells and a gene CDMO for the It biosciences vectors is cell hold the cell. a Their therapies our rate market. growing part after have

believe contribute and depth new Given customer customers capabilities meaningfully our of to breakthrough we can helping launch therapies. our we reach, scale,

confidence us. And of pleased our The we're making we're benefiting regulatory progress projects sterile to with will pharma The biologics, benefit. expertise. we're summary accelerate we with building their of global of well. these the gives our give so through and summary, of strategy markets Business System, our strategy activities company, about combination Italy of and, transaction this investments We're In positive let Monza manufacturing by a capabilities. another provide the network. at sites this our work our Greenville, It's services in year. development foundation in Last quality hearing and expanding and from business our services. who you a this million manufacturing manufacturing is who experience behind disciplined we this to capacity opportunities most to development rely month, investment $XXX and PPI performing comment are business world-class Thermo our and these in example the in our far closing from strong example, quarter. outsource from North capital customers. Ferentino, feedback capital quick incredibly of bringing expand we customers demand investment is For to our to and excited and M&A combination and M&A. course, patients the very and a our customers look work, with to This the for our part regarding finally, These is on expanding drugs the meet increasing deploying our additional and very at capabilities on Fisher. We're -- CapEx deployment final capabilities our further Carolina. note, announced capacity building customers building systems. importantly, One essentially our integration critical business represents that expertise and On to me build activities This pharma tremendously capacity forward

As acquisition Brammer of mentioned, in Bio for announced cash. $X.X we billion our I just

significant returned dividend also stock capital of our our million January We the shareholders by repurchased We during quarter. in to and XX%. our also increased $XXX

to start the remains M&A active deployment and robust. year the front, an So very our on capital pipeline

turn now to for me XXXX. guidance Let our

guidance in are new acquisition Brammer year. reflects we which release, performance raising full into represent strong our to of earnings but range our expect revenue of will X% operational As both press revenue in you QX over This as cover saw to will let X% to highlights. the XXXX. primarily $XX.XX our our Stephen Bio, billion to our the We're behind billion, and which the guidance, raising we and a $XX.XX mentioned, for I me growth guidance get the QX. in assumptions close

growth of raising terms our will share, EPS, adjusted $XX.XX X% range of to guidance per XX% to to to which new In we're a lead $XX.XX year-over-year. our

delivered Before over to of summarize key line. QX. Stephen, takeaways another me top We both let on financial and I call the bottom the turn our quarter excellent from performance

value significant effectively With turn proven to share. to We We that, our call be to strategy an deployed continue Stephen our our create CFO, and gain partner customers our execute our Williamson. even growth Stephen? shareholders. for to over capital the our I'll and stronger for customers

Stephen Williamson

an our color four I'll providing first morning, the you good updated for and quarter overview through everyone. and results on conclude provide company by take Marc, XXXX segments, our guidance. Thanks, I'll then our total of business

a I call quarter get me details earnings in our provide the at of our played out our of high-level into versus first Before time view performance, let how of the January. last expectations financial the

in versus from $X.XX quarter adverse original This As of gains operational by organic a our delivered the release, quarterly of and higher you This than execution. adjusted was our by EPS benefit planning X% growth great in very less and strong by enabled tax $X.XX is at previous press quarter delivered we'd guidance. our of in in We assumed FX conditions continued operational $X.XX midpoint we driven phasing saw the driven that QX. market strong was performance, guidance. share with $X.XX initiatives

So off the to year. great a we're start to

Now earnings more starting share. let detail me on per QX, cover with

This XX% to from quarter EPS quarter, was adjusted QX XX% the we $X.XX. last grew year. EPS up by GAAP $X.XX, in

X%. On X% of growth QX growth, of increase components line, acquisitions and foreign from our revenue The organic included the our X% X% year-over-year. exchange revenue grew top reported reported headwind

Looking at growth by geography.

Our markets both and in the grew digits. the globe. North remain across America mid-single strong Europe

world and over rest quarter we of both the in XX%. in digits. China, Pacific the double had Asia great another grew And growing

last volume investments XX.X%, year. operating operating XX business strong strategic from our offset X%, Business productivity good points and of adjusted PPI partially to System by increased margin unfavorable saw operational Turning QX leverage, was our and QX We performance. basis income adjusted from mix. up and

growth operating a impacted quarter and exchange the income by our basis XX headwind Foreign was negatively over of on just X% points. in margins

quarter, details QX compared businesses. continue we was driven last X.X%. of margin last productivity in and to XX.X% Moving pull-through P&L. a strong as R&D R&D versus of and in in is of year. XX strong to productivity came strategic revenue, Total QX which company manufacturing our top QX Adjusted QX investment. business the mix as by actions. at to the basis revenue XXXX, our Total was was offset quarter the flat adjusted on reinvest growth percent QX X% a points year and to the And line XX.X%, unfavorable in expense flat volume was SG&A in gross revenue, In of by down

year, for Looking other income at nonoperating primarily Adjusted million, to the higher in quarter. of the million, reduction. line primarily our below $XX was by million interest expense results $XXX Net $XX quarter QX changes income approximately due expense the than net was down driven exchange. from XXXX, QX and a foreign debt last in

mainly average tied X a QX our as share tax adjusted partially primarily QX was dilution. our basis QX year-over-year, buybacks rate reform. XXXX, were the diluted impact shares driven option by by of lower lower XX.X%, which is than planning which of tax initiatives Our is XXX million offset million, U.S. points XXX tax to result

flow Marc after flow continuing balance QX flow million. was and Turning in Cash from net the capital investments. deployment, $XXX in an quarter. capital to was cash of and deducting was expenditures quarter $XXX as with active terms million free the said, We sheet. million, ended $X.X And QX operations and cash $XXX in million of cash

of Bio. M&A, January. billion dividend. increase million share the XX% $X.X were in Brammer $XXX with we And announced We with February, a shareholders to capital for acquisition return active our to committing continue We buybacks of also in in

in capital of quarter. taken actions first over deployment So the $X.X billion were

down sequentially end from QX. of Our was $XX.X total million the QX $XXX billion, debt at

to the our performance. To my adjusted up at EBITDA. end was X.Xx company ratio total the quarter total on wrap comments leverage debt of Our

and and to ROIC, XXX Science good year. very X%, increased In XX.X%, Life performance grew Science good our businesses. in of in We and continue pull-through continue business organic X% productivity, volume investments, last reported strong which QX volume very adjusted increase the foreign segment the a with this margin from in sequencing we margin very X Starting business strong headwind up by led points In Analytical drove reported XX.X%, and provide segment. quarter, Instruments we revenue was revenue X%. I'll X%, was strategic organic the in impact and QX at increased Instruments offset Segment, the to QX growth good unfavorable adjusted operating income exchange. exchange, growth In year-over-year. our Solutions foreign revenue X%. basis clinical very is is up to this operating quarter, this we partially see XX.X%, adjusted QX, mix. some our unfavorable basis operating offset now saw In points and growth XX Analytical productivity bioproduction, now In Life up by was adjusted XXX mix growth across increased points continue we and income and and which basis all on businesses Solutions. in revenue favorable the partially of from in XX%, by see quarter, next-gen QX leverage was investments strategic operating quarter, and color business year-over-year. In the biosciences segment, segments. the from

year, margin volume quarter, mix. and from operating income favorable operating was the to were businesses. flat Adjusted In good revenue organic year. led business growth saw our was grew points growth X%, X%. we prior Turning diagnostics down total In by basis XX.X%, Segment. and the over prior the QX, Specialty clinical was adjusted in versus Diagnostics and XX In revenue and segment, this leverage the segment immunodiagnostics

investments. by However, was offset this more than strategic

was which reported products lab includes segment, growth revenue year. we the our across the offset business quarter, the QX increased than In Segment, strong and Services of unfavorable strategic investments the growth we in segment in services, good prior pharma leverage. channels X%. all was quarter, saw XX income by points and X%, operating and increased Finally, In volume margin operating strong saw which and adjusted lower is XX.X%, was research the in mix. businesses businesses. Adjusted the than Laboratory revenue more Products X%. a and This basis Organic productivity

full to guidance. to on I'd year updated like now our So move XXXX

we saw as and our mentioned press revenue earlier, you guidance. adjusted both raising Marc and in As our release are EPS

the $XXX raising guidance of revenue. increase tightening me range I'll revenue elements. midpoint million you of $XXX The million. details. $XXX by begin to walk Let the the the million through our We're with and midpoint X by consist

growth First, organic $XXX reflect in performance. the to million our strong increase outlook on for year QX

a guidance our organic that growth reminder, XXXX and As we QX XXXX. between be year X% initial for growth organic to assumes strong X%. and in expect guidance the reflect full a to raising We're year X% performance, now

which in of guidance element increase reflect our second The we to Bio, of QX. Brammer to during an is the the expect $XXX of million revenue acquisition addition close

revenue, now for few X% with revised XXXX X% X% is our behind rate A revenue XXXX Turning The guidance the increased elements: previous range continue reduction $XX.XX our versus To FX strong to environment the range Bio, in impact year the guidance $XX.XX or starting of to updated $XX.XX increase guidance, to XX% this sum a rates $X.XX FX versus account represent X be which to Currency million, EPS our approximately addition so will have to We're increasing billion, assume revenue QX is to versus and on Brammer XXXX. up, of guidance. full a changes mix our growth $X.XX FX change $X.XX of no details net midpoint would XXXX. The for a more that the to consists $XXX to would we our to EPS midpoint of $X.XX. reflect headwind guidance now the billion of a represent of XXXX and other adverse growth increase $X.XX adjusted $X.XX operational reflect adjusted the $XX.XX, which to per earnings range continue FX. QX. tightening of adjusted by of on X.X%. a share. by the And to a performance,

which of now the of the to divestitures. in changes expect in both divestiture change of which Pathology headwind I incorporate business FX with However, year. the Bio to to $X.XX and does and assuming impact QX, trade guidance. for January. want rate or include pending adjusted dilution the to or full divestiture continues did of to we no We're Pathology the for Anatomical of the $X.XX FX environment versus acquisition, a that tariff our previous we there's announced be Anatomical mix business, in note net close XXXX exception are in X.X% Brammer pull-through, The future EPS any expected the not the of our the guidance acquisitions guidance

XX.X% a full As to $XX to I million that points is adjusted guidance last tariffs the quarter, of which EPS are approximately impact of from our XX Adjusted includes in mentioned annualized year-over-year and would result XX.X%, $X.XX place. tariffs margin reflect growth now for headwind or XX to the expected about of currently to year. the operating between expansion margin be basis in

will Moving tax repayments continue to below $X than our million, debt previous XXXX adjusted XXXX, is we we previous guidance, continuing billion the guidance. be million. other expense approximately interest lower $XX Presuming million rate the million $X.XX to $XX our net than expect to expect We're and that be about XX%. is $XXX higher be about income of assume This which net in to line.

higher rate due the be Bio. million at QX year, capital in mentioned made to facility year. expected to assuming our now XX.X% the will the to $XXX net We're factor lowered no timing discrete in I Brammer had This we closer for and million to the within $XXX quarters to in is investments expansion As expect change we expenditures of remaining year. in guidance be the than the that the a to items previous earlier, million XX.X%, full between $XXX rate and and tax planning be

approximately cash to our million year And billion. flow the $XXX as approximately full We the offset with operational cash CapEx result, Brammer to shareholders $X.X free we'll will change year phasing estimate this approximately be a on of prior return guidance. estimate of that flow to year million, million continues And expect few a comments diluted average performance. increase capital we investment assume from We dividends, guidance. finally, for the previous from year. X be And shares through no an for the XXX full quarterly strong our

Our expectation QX, the guidance. level unchanged growth and for revenue of organic QX prior our from in is QX

In terms remaining a for similar EPS, of period the adjusted X XXXX. phased the in we it'll of expect months be months those in X across that year, way to the same

summary, So year. an over in achieve the QX, in for we great started I'll year excellent we're call turn a to position that, our to and with the goals Ken. the With back

Kenneth Apicerno

Operator, to we're Stephen. now Thanks, take questions. ready

Operator

Instructions]. [Operator

line comes question Muken Evercore Your Ross first from ISI. from the of

Ross Muken

Congrats.

and end biotech of So side. food ex innovative for true right like of up, on were yesterday, your some we're call print. push on mix, about obviously, I sort of seeing some about huge based your and China. guess, And obviously, we the remarkable peer coming China China, But don't academic, of know pretty obviously, the your if sort seemed as that generics holds strong. a much see know markets, maybe some I peers out now off It areas. other you moving business think parts the commentary to of in the

run had, time. has you of be up some now bit that for little So business -- obviously, where a China would remarkable on start, a because this helpful maybe has XX% quite to commentary a just put been sector

Marc Casper

question. the you for Ross, thank

We with in had it momentum. was and So in customers. of early I some China were terms bookings and stronger quarter. broad-based I We team, government April. our had good time a revenue, in very the than spent was that

the really didn't in Chinese we any So see markets. end headwinds

in good Pharma in and had health that quarter and biotech that to government care, okay, was market, but we fine. diagnostics and had was the was also Industrial So academic exposure smaller and we a sector. fine, too.

some the us, to challenges, see have ahead super got and cycle time didn't a spending of the market, the momentum for we I some teams biotech very very say, to the customers it's long a with a looks in environment. going future. of long any growth excited and -- of there lot So like have the positive

Ross Muken

not revenue on overall, but your maybe Obviously, exciting business. Brammer. super And a huge a comparative Helpful. quickly base to

going a market. give general the gene of the sort sort capabilities that and to the you over evolve. how is could logistical unique think bring sort that market manufacturing Maybe of of of us And that, about with you guys kind currently some bit therapy how feel time, You to theoretically, help of just faces? in side a and of of challenges bioproduction that

Marc Casper

capabilities build expertise and landscape is, was of confidence is the have right customer gave the base. therapy things off set heard the is in us to of. platform been investing the us serving whole our the big at that need the scaling very significantly thing new opportunity reasonable broad the broadly experience of leader one biosciences gene about, our in that is and partners. of bioproduction and actually very through are Brammer customers quite to that's have a pharma excited base as consistently we across they the that Ross, to help. our viral the And area industry and we therapy have exposure the gene that the segment and and with services one asking and business. process, have already right regulatory interesting where for something ramping-up We production have development vectors And a looked in bit going The business the we

serving excited expertise. the with use exquisite our an about set to industry going We're we're very So of capabilities. regulatory

look to that So quarter. this acquisition we forward closing

Operator

And your next question comes from the line from of Tycho JPMorgan. Peterson

Tycho Peterson

another ask on apologize. question going Brammer. I'm Marc, I to

early couple Sarepta, here of a got and You've customers Sangamo. with Voyager

over diversification we pipeline. the customer time, about think about as you curious Just how think

that how in year you're heard much fees but $XXX is the revenue that that's million If peers on from of actually And charge some used. comment your already in reserved contracted? space willing can then we've capacity you on to this not

just So talk low lastly, And business? I'm manufacturing may some a curious about potential the we different be about know it's for EBITDA the with whether pricing bit margin of see little I that then could if opportunities than in XXs. other that you businesses. space

are the some target. kind mid-XXs think XXs of I of with businesses high pure

So come. the to just curious how margin you think about opportunity

Marc Casper

Yes.

mix, So have a others terms Brammer number years been customers, Tycho, of there's in a the are of over and confidential. customer few announced the publicly by

And mix good there's So of customers. a good mix that's within a even the customers, programs. of

has we that you program we're going is So ultimately, because and it mix. Because the successful, further customer base to every have, interesting over thing of time. customers of expansion the nice relationships be diversification. that's capacity have about not is that diversify excited to The so going a

So attractive Yes, the capacity. there term of this because a in because that's shortage real good. the short pricing -- very there's is is market in pricing

So reservation there associated as as economics benefits economics. with terms contracts the industry have industry the that of of But in scale. get you many our from capacity improve further the therefore, helps the fees because and And are leverage. scale the with then economic finally, And -- outlook. scales, comes it, online,

our see to time. margins where below to be opportunity this, For over average are right a accretive now margins and we the company little significant

Tycho Peterson

changed into Has then capacity announced And the Sticking there kind how And maybe is equation? Advanced biomanufacturing of acquisition your the with at expansion just Patheon Okay. fitting up. as piece, Patheon well. part the follow as revenue view synergies of on a Bioprocessing you the all? that obviously,

Marc Casper

Yes.

Revenue's side. closed good And accretion to really off the we Bioprocessing, good. think within this I good. to a bioproduction product our That January, been $X.XX was in Stephen, say, bolt-on acquisition business is Advanced start. I'd of Earnings year. it's on So This are a $X.XX in October.

So going that's quite really well.

Celltrion strong. have fact continue because capacity very have the demand the just it utilizing for -- own customers terms -- we we on to within is our of network expand capacity announced within on that is biologics that comes network very, In the The we the expansions bioproduction interest based that the expressed line. portion, that as

growth mid- we're a And ultimately, start. that from perspective, So to a business, the we'll And into see transition high of well. business. which it's off kind to a was we historically single-digit revenue business, good synergy going

Operator

Schenkel Cowen. Your next the Doug from of line question comes from

Doug Schenkel

China. just Marc, follow-up So quick a on

You entered would the assuming mid-teens. year China grow

embedded guidance. assumption the was that think into I

the year? we comps we more expect over full Or Should mid-teens now in balance still better XX% get same of of should growth year? north than assumption China the grew bit the maintaining be quarter. first for You a do for difficult the given the

Marc Casper

Yes.

So QX banked in operational was the quarters as we Doug, And January. the -- for were than performance both X had guidance, did on we the over whole, we way as in operationally. originally that a back the remaining that outlook guided is higher the assumed and year the revenue

XX% China assumed actually, the for on the mid-teens-type in head, did We, we over QX. growth done obviously, math my -- year. the in but haven't So

to our the going quarters mid-teens that's relative change it I to high the math, haven't next January for teens. take probably done strong the guidance. low but So to to three haven't we outlook

Doug Schenkel

that's helpful. Okay,

capital billion next M&A deployment On more than the with cash. $XX year, of our capacity side, that's by have Brammer you over that's still factoring in the estimates, and and just

it's the market, growth given these, some the today actually wondering about market. Or means take CDMO I'm possibility that just if the a M&A your using in there's do and most your in in going you're doubles criteria Brammer given Patheon, Bioprocessing capacity or are and all look are? bioprocessing including of given more whether recent If Advanced likely to And fragmentation How other equity, our were you of prioritization math. more you acquisitions, of the where valuations likely rapid of to CDMO areas? the thinking especially by

Marc Casper

Yes.

have substantial we So capacity.

with the what customers? And last industry. criteria create is up. first company our at measured The we job have do Will it, for we that are as value is have the is, same ultimately, will used everyday the the right? and shareholder thing years, wake which incredibly on environment, M&A right? that's have, I we it strategically? the XX priority to be capital we our then business strengthen XX, And by great run an a it transaction by valued look will returns when we we So #X the And the fragmented do invested

is very robust. Our pipeline

very great ones looking. very And that going active and looking go But and portfolios. transactions, we're across the we're really only to So do to we be so hard we predict it's feel through, will all are right? transactions which

all or read So that wouldn't based. it's biologics bioproduction I over

asset is, expansion Brammer, advantage the part and looking of selling of noncore think took for really, it as a BD I opportunity was boost we capital. real in was a

see those but we'll you'll that do. to transactions, good, the those situations And So us across look portfolio. are led

Operator

Jack next Your the question line from of Barclays. comes Meehan from

Jack Meehan

and up we hoping was life I could semi? on have could and update you sciences across turn Analytical to the FEI of material just And Instruments us Segment. sciences versus the backlog please give growth shaping an

Marc Casper

Yes.

of So had electron Material our X quarter. business, molecular and good Analytical growth the in Instruments our includes spectroscopy, strong good with businesses quarters growth. in which sciences, terms microscopy all had of the the

materials sector, sectors. segments you -- biology. science good research, the the advanced also of primarily life the and academic Revenue includes in both sciences which terms In structural was those segment, growth you semiconductor, batteries, material have of have

in portfolio in As second portion science the forward. know, challenging -- we more you going that half have growth expecting materials we sector the comparisons product because are slower of

expecting, slower growth the second in delivered will that we the as we're first the So originally we be half guided, quarter. that than

Jack Meehan

digits. Great. conditions And markets called any then you some high applied single side muted at and saw? But And those were was change there. what that then, Europe I was Europe, curious the grew I academic more industrial guess, I you on overall seeing. regionally there end you out in regionally in know looking

Marc Casper

the We diagnostics really biotech. end in and aggregate conditions of the Europe, actually, saw health Europe. growth had across quarter. muted care good industrial more X was X that pharma and applied, good. We in and ran a markets, and And in

bit other So release -- where was funds, geographically, -- but of the probably muted little than more a area on Germany that... an and

Kenneth Apicerno

On the academic government... and

Marc Casper

and academic On government.

actually It a had but called recently. softer seen very as just we was that and a fine, was academic out in Europe, solid government right? bit -- it So because growth, was it little I whole region was than

Operator

comes line of from your Bank. question Deutsche Leonard And from Dan the next

Daniel Leonard

you back the what business? So trajectory the manufacturing put that would there? commentary And on the margins that business trajectory? in Is the How view first LPS do appreciate segment. primarily off, on a contract expansion margin

Stephen Williamson

Stephen. is I'll this Dan, one. that So take

driven about -- be term, when margins by is the segment So going it's services business. LPS, pharma think for expansion to that yes, in long I

we investing putting been It's preparing we're businesses in where in on guide, side. investments the in outlined we're sterile and on that As the growth. for synergies the in original driving place biologics ramp revenue

year, long-term So there. more forward this margin but expansion growth good going muted prospects in terms of

Daniel Leonard

you my was to bioprocessing players? us participate? you there's you're Can viewing incrementally feel bioprocessing see that where opportunities then the the do you And And Thermo -- away front? offering only remind amongst on an yourself traded do expand product in reasonable Is acquisition few opportunities your follow-up. product Okay. there you concentration areas this a quarter. opportunity to how there Marc, a from for

Marc Casper

Yes, Dan.

business position Life It a We went have the being started methodically in of a player becoming done have to whether transactions in in strong offering, where our from culture business. the to building was controller leader the media. single-use BD's our from with a Finesse, then acquisition technologies strengthen cell ASI, of acquiring series bioproduction We actually been time. technologies we over Technologies, it adding

the and where profiles So returns. can about our on M&A. we of parts very We're return on look portfolio strong on strengths generate we the our build disciplined

that which continue have see opportunities, So in things, sense. and if we'll we us opportunities of at make right terms think look And about more. do you'll to see you the to

Operator

next question comes the Donnelly of from Sachs. Your Patrick line from Goldman

Patrick Donnelly

able single-digit see pretty industrial, a strength tough Marc, going Which just comp. and put about durability nice Can there you pockets talk strength? some high you to you're market, against applied seeing the really the Maybe, just forward? growth be to Great. single-digit up on the high guys

Marc Casper

Yes.

a the because, year expecting and year there's within So we industrial visibility ended start the how to were in obviously, applied, strong some from our bookings.

that saw chemical the and a it saw it assuming going we're electron the single-digit half analysis, And it high going in of bit be saw challenging in year softer grew So in spectrometry. more second We to the microscopy. what mass And in comparisons. we chromatography quarter. we and little is that is strength, we growth in the given

kind that So the on view market. that's of

Patrick Donnelly

then off are as and year, Analyst X% quarter X% the here. an you Day guys coming we month, approach Okay, next growth growth

help just Can perspective guide are ahead You Analyst that What you there. long-term out of we the have to you thoughts put that where Day? long-term versus are that of rate? currently X% growth us terms of kind X% as in your plan

Marc Casper

Yes.

As best New XX the May and I year was City day as team always of in the is my at York there the coming looking calendar, It's up. smiles.

long-term get in you will our be I the that of of each that. Stephen community. year to of know model about as I front So and and three part investment the And talking wait outlook can't

be good at that a clearly we'll discussion of So back time. topic point in

Operator

comes Dan next question UBS. your Brennan line of the And from from

Daniel Brennan

just deviations you wanted start on to whether were really quarter. point Congrats regionally, can maybe biopharma. robust another Great. Obviously, I quarter. big the just to can with there you Marc, there? And point any out and would you kind where the color you're most the your share came interested related cited of gains, so that, share to some the be within gains And from strength in seeing businesses? on then opportunity. where

Marc Casper

strong. in our research our of about the Yes, really for lines, pharma when we strength the the I is saw at digits. the the And very Bioproduction, Dan. biotech spec, in Thanks and grew pharma market, mass terms When channel We end chroma portfolio. growth. had excellent safety services look I business question. the market think double across and all quarters business

as clearly we at strength And is very funding part was share. that it have broad-based it been time. in any science was of Geographically, across anomalies the is good the So but I gaining geographically. of strong for seeing good, is and, didn't we regions, see think some we're markets. good, so quite that I any looking

relationship to And we as access customers. the truly terms unique and productive. gives we unique is very us our the us help proposition strong reach more value gives have customers innovative Our well. incredibly the access that each of customers those to be of how in scale commercial of And

quite combination very for has performance that So strong some sustained time.

Daniel Brennan

your Is what biopharma color what China between the may be or to business like push Great. the China So on look kind you over more related Can elaborate can highlighted excitement maybe Marc, today just looks it to And branded-oriented? for going some growth and that, then that in China there. that of be you future biotech forward? a just can like be in in bit? therapeutically-oriented

Marc Casper

Yes.

and a China on pharmaceutical medicine. the industry in about perspective, roughly, ago, side years and blend Chinese we when five a were generic biotech was from pharma of So traditional manufacturing thinking the it

Over that in has traditional and the of continues very to an addition in there company last bright side explosion medicine, Chinese terms small biotech molecule and X been formation the really new the and of years, to look on growth, interest that very China, up, outlook. customers the companies And the exciting they capabilities. well. with standardizing our opportunity, familiar are very because technologies. It's have they're of on an our we're setting the many really and doing outside are of And worked

Operator

comes question next line De Merrill of Derik the Lynch. from from America Your of Bruin Bank

Michael Ryskin

Derik Mike is for on Ryskin actually. This

negotiations bit You U.K. touched you've ongoing. to follow specifically or on are sound doesn't previously, are embedded cause the an potential Europe thoughts the focus on we the I want as But but see move through little in as just guidance in like recently your Europe concern. It of to year. a as up want Brexit. impact seen a of I what any what's been in area kind That's the and Northern

I to you're that. see want about thinking how So

Marc Casper

Yes.

work terms of the continues of down can We Brexit, preparation really And that's while. it's obviously, small but for market, last a lot a been U.K. week. -- the conditions did be to In kicked effectively fine. were a

prepared material in happen it but of be to towards flowing terms So any seem in market that business way, conditions. doesn't should negatively, we're or positively our

Michael Ryskin

follow-up. that All update other XQ? some on Gatan. capital and right. an of events divestment quick then deployment The Anatomical Pathology us then an a also on expected of And terms you update give of Could timing are the in in

Marc Casper

Sure.

We events acquirer the that on closing the clear the to expect just we did divestiture working we of need and business. with conditions now on the in all close that So the regulatory all Pathology clear, to of Anatomical QX contract. we're

in as expect, close also the We Brammer acquisition said, Stephen to QX.

Gatan, Markets Authority terms working resolution, challenging. U.K. to have a Roper Competition and been of with come and it's well as In the Technologies, we are, to as reasonable been

QX. get their We the of expect final end to by decision

Gatan. are we where that's with So

Operator

next from Cleveland comes Your question Research. from the of Willoughby Steve line

Stephen Willoughby

questions couple for guidance of you. A

quarter first And midpoint bps just only up full so $X.XX, attributing on First, you the that. by really Stephen, year, the then XX you're you the I the but at bridge believe beat earnings then wondering were the operating beat, for quarter that expectations said $X.XX, in quarter. first secondly, in here your margin to first

in more against going organic year. comps the difficult the remainder of growth You're

we'd growth expect organic So to slow.

growth Just of the wondering, margin what's with in expansion organic the believed to terms greater what rest margin be gets slower expansion, year. of

Stephen Williamson

Yes.

of in So X, we revenue. $X.XX year, for And of Steve, is unwinds guide, each rest $X.XX benefit that in as QX. and in terms QX of then $X.XX That's which year the of the the for and had QX, positive changed, at FX the pull-through versus $X.XX quarter QX. adverse then a which timing was of was FX. below-the-line the that tax, kind to a change actually in the And out QX The the FX. of the as was $X.XX it's net difference, on $X.XX you a go we original way $X.XX look more rates FX

full the but the to forward year. operational -- So $X.XX carries

idea of The gives our headwind also standpoint that And timing $X.XX The of the bridges the is from XX for which of sizable. from the delivered It's projects revenue down lessens away. profile in to helps And from and second a of And the $X.XX. basis that well. of spend, an headwind well. XX you that's comes points into gross year. and quarter, so tariffs then markets the kind as year, points still as with the basis in as offset included declines certain QX an it then the terms to about of really that's as So this margin headwind FX we the the XX points tariff of then on that FX standpoint, go of of from -- rest you we half points. basis and headwind basis the the a for reminder, just as that the scale goes

Operator

line question from the next Your Sung BTIG. from of Nam Ji comes

Sung Ji Nam

how further Specialty are And to segment going the as potentially this there business is for talked Marc, opportunities of If given I be ones. top quick of couple asset just your to in critical laggard that but Is mean don't a line nitpicking could to kind was nice strategic it for point, have? And where that you on Gatan, also back a is asset to Just you segment. at you curious accelerate Diagnostics. investments cryo-EM to about Stephen, that? growth for some terms overall? then of comment -- could a growth,

Marc Casper

Yes.

for thanks the question. So

terms did that microscopy with first, nice or So a not. our closed sign long-term think Gatan, whether a we'll electron supply of we it's We business, Gatan. fit in gets and relationship with see new

it close, the has outlook electron for business. negative impact doesn't it if strategic microscopy on no the So

a that's nonfactor. So

first the In good terms and the is making have, and progress midterm. of on still we Specialty I the performing in the growth in mid-single-digit solid and reasonable that Diagnostics, delivering product includes quarter. of when well business benefit powering think quarter, in growth the about headwind we're that growth development the through a should level that And flu programs

Operator

comes Paul of from question Knight the next Capital from Janney Markets. Your line

Paul Knight

multiyear as Do about the this well, visibility a tone on guidance? Or growth Marc, the current the the organic industry think on in organic and the think if year's what's look? you it's it going customers you that's thoughts are and your industry look? and in is financing that? look your you What see on

Marc Casper

Yes.

outlook at to a the strong. market, I'm diagnostics and life look fundamentals, and they tools the if the science I when looking absent see very -- recession for macro So look

biotech investments it. of You're the and excitement terms and pharma that support in in seeing the science

looking You see see very good. to it that you biotech, in going funding

excitement the look especially world, there's U.S., at and in is kind that you in Horizon looks If globally, side academic commitments on commitments China world of a plan in academic continues a X-year real have governments, NIH to new and a there that Europe, the program big the the around post-Brexit there a outlook about robust. to a U.K. the gives to the

care to continues go the can control diagnosis, really, costs get is the outlook way because, so benefit actually bright accurate to patients. a you're money there, medical only So right things diagnostics health and spending have you on you that if

that out, at looks you over see any at you on about positive at years, the predict, slowdown in point other look be science the exposure super tools in never thing the in And growth. great. came great when some great -- to recession. look industry. volatility So there'll saw when what's in our But X life factors. the going knows, can recession I and We the sectors incredibly who our It's business some And don't our is the fundamentals, economic next, performs recessionary low a have. diagnostics industry

about outlook our we're So the bullish industry. in

Paul Knight

lastly, pace channel over investment of of selling CapEx is then been has the of your your know -- advantage last your the specifically, And several is same and I and IT I market? great distribution keep Marc, advantages how more maintain CapEx infrastructure, it in the do one Is your And product years. you requiring a barrier the there or CapEx? Or that mean, not?

Marc Casper

Yes.

create because to rate had platform. our invest we historically that And substantially our leading fantastic historically for leading created we at effectively, that invested that than experience e-business maintain a platform lower we we So have are e-commerce a and investing a And and that to advantage. continue have build to which build we lead, we what customers.

to you add thermofisher.com, strong So those or sure own. capabilities. our our new And site if we'll go see make to maintain experiences Fisher yes, we And invest continue we how to are. to continue you that

Kenneth Apicerno

of going about right it we're out just to end time. Operator, We're there.

Marc Casper

to start. support ongoing another just Thermo So track Scientific. wrap me as your always, by a Thanks, off you on for outstanding summarizing year. thank everyone. And let Fisher strong We're to that up of we're deliver

Operator

now great This concludes today's a conference call. and Thank you participation may you your disconnect. for Have day.

Thermo Fisher Scientific (TMO) 24 Apr 192019 Q1 Earnings call transcript